Cover Page

Cite item


We analyzed clinical data of 253 patients with lymphoproliferative and plasma cell disorders and kidney damage, and clinical and pathological data of 128 of these patients with histologically proven nephropathy. Broad spectrum of histological variants was found, and correlations between clinical diagnosis and pathology established.

About the authors

E. V. Zakharova

S.P. Botkin City CUnical Hospital

Author for correspondence.
Russian Federation

E. S. Stolyarevich

Moscow City Nephrology Center

Russian Federation


  1. Бирюкова Л.С., Тангиева Л.М., Тимохов B.C. и др. Комплексная терапия хронической почечной недостаточности у больных миеломной болезнью//Нефрол. и диализ. 2002. N92. С.98-105.
  2. Бирюкова Л.С., Тимохов B.C. Нефрологические аспекты заболеваний системы крови//Тер. арх. 2003. №6. С.73-79.
  3. Ромеев В.В., Козловская Л.В., Когарко И.И. Новые возможности диагностики и мониторирования AL-амилоидоза//Тер. арх. 2010. N96. С.29-31.
  4. Рехтина И.Г., Голицина Е.П., Варламова Е.Ю. и др. Морфологические и иммунохимические особенности нефропатий при множественной миеломе с тяжелой почечной недостаточностью//Тер. арх. 2013. №3. С.80-85.
  5. Cambier J.F., Ronco P. Onco-nephrology: glomerular diseases with cancer//Clin. J. Am. Soc. Nephrol. 2012. V.7, No.10. P.1701-1712.
  6. Cohen A.H. The kidney in plasma cell dyscrasias: Bence-Jones cast nephropathy and light chain deposition disease//Am. J. Kidney Dis. 1998. V.32. P.529-532.
  7. Da'as N., Polliack A., Cohen Y. et al. Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemia: a retrospective study in 700 patients//Eur. J. Haematol. 2001. V.67. P.158-160.
  8. Magier K.T., Lynch J.W. Jr. Paraneoplastic manifestations of lymphoma//Clin. Lymphoma. 2004. V.5, No.l. P.29-36.
  9. Heher E.C., Goes N.B., Spitzer T.R. et al. Kidney disease associated with plasma cell dyscrasias//Blood. 2010. V.116. P.1397-1404.
  10. Herrera G.A., Joseph L., Gu X. et al. Renal pathological spectrum in an autopsy series of patients with plasma cell dyscrasia//Arch. Path. Lab. Med. 2004. V.128. P.875-879.
  11. Keeling J., Teng J., Herrera G.A. AL-amyloidosis and light-chain deposition disease: light chains induce divergent phenotypic transformations of human mesangial cells//Lab. Invest. 2004. V.84, No.10. P.1322-1338.
  12. Korbet S.M., Schwartz M.M. Multiple myeloma//J. Am. Soc. Nephrol. 2006. V.17. P.2533-2545.
  13. Leung N., Bridoux F., Hutchinson С.A. et al. Monoclonal gammopathy of renal significance (MGRS): when MGUS is no longer undetermined or insignificant//Blood. 2012. V.120, No.22. P.4292-4295.
  14. Leung N., Dispenzieri A., Fervenza F.C. et al. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis//Am. J. Kidney Dis. 2005. V.46, No.2. P.270-277.
  15. Nasr S.H., Markowitz G.S., Stokes M.B. et al. Proliferative glomerulonephritis with monoclonal IgG deposits; a distinct entity mimicking immune-complex glomerulonephritis//Kidney Int. 2004. V.65. P.85-96.
  16. Ronco P.M. Paraneoplastic glomerulopathies: new insights into an old entity 11 Kidney Int. 1999. V.56. P.355-377.
  17. Ronco P., Plaisier E., Aucouturier P. Ig-related renal disease in lymphoplasmacytic disorders: An update//Semin. Nephrol. 2010. V.30. P.557-569.
  18. Royer B., Arnulf В., Martinez F. et al. High dose chemotherapy in light chain or light and heavy chain deposition disease//Kidney Int. 2004. V.65. P.642-648.
  19. Sanders P.W., Booker B.B. Pathobiology of cast nephropathy from human Bence-Jones proteins//J. Clin. Invest. 1992. V.89. P.630-639.
  20. Weichman К., Dember L.M., Prokaeva T. at el. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high dose melphalan and autologous stem cell transplantation//Bone Marrow Transplantation. 2006. V.38. P.339-346.

Copyright (c) 2014 Zakharova E.V., Stolyarevich E.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies